UA70294C2 - Use of cyclooxygenase-2 inhibitors as anti-angiogeuse of cyclooxygenase-2 inhibitors as anti-angiogenic agents nic agents - Google Patents

Use of cyclooxygenase-2 inhibitors as anti-angiogeuse of cyclooxygenase-2 inhibitors as anti-angiogenic agents nic agents Download PDF

Info

Publication number
UA70294C2
UA70294C2 UA99063447A UA99063447A UA70294C2 UA 70294 C2 UA70294 C2 UA 70294C2 UA 99063447 A UA99063447 A UA 99063447A UA 99063447 A UA99063447 A UA 99063447A UA 70294 C2 UA70294 C2 UA 70294C2
Authority
UA
Ukraine
Prior art keywords
phenyl
trifluoromethyl
alkyl
methylsulfonyl
pyrazol
Prior art date
Application number
UA99063447A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA70294C2 publication Critical patent/UA70294C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
UA99063447A 1996-11-19 1997-11-19 Use of cyclooxygenase-2 inhibitors as anti-angiogeuse of cyclooxygenase-2 inhibitors as anti-angiogenic agents nic agents UA70294C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3140496P 1996-11-19 1996-11-19
PCT/US1997/021489 WO1998022101A2 (fr) 1996-11-19 1997-11-19 Procede d'utilisation d'inhibiteurs de cyclo-oxygenase-2 comme agents anti-angiogeniques

Publications (1)

Publication Number Publication Date
UA70294C2 true UA70294C2 (en) 2004-10-15

Family

ID=21859277

Family Applications (1)

Application Number Title Priority Date Filing Date
UA99063447A UA70294C2 (en) 1996-11-19 1997-11-19 Use of cyclooxygenase-2 inhibitors as anti-angiogeuse of cyclooxygenase-2 inhibitors as anti-angiogenic agents nic agents

Country Status (19)

Country Link
EP (1) EP0941080A2 (fr)
JP (1) JP2001505564A (fr)
KR (1) KR20000053362A (fr)
CN (1) CN1247470A (fr)
AU (1) AU730211B2 (fr)
BR (1) BR9713522A (fr)
CA (1) CA2270469C (fr)
CZ (1) CZ176899A3 (fr)
ID (1) ID21979A (fr)
IL (1) IL129604A (fr)
NO (1) NO992309D0 (fr)
NZ (1) NZ335853A (fr)
PL (2) PL194717B1 (fr)
RO (1) RO118566B1 (fr)
RU (1) RU2268716C2 (fr)
SK (1) SK59999A3 (fr)
TR (1) TR199901703T2 (fr)
UA (1) UA70294C2 (fr)
WO (1) WO1998022101A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2475257C1 (ru) * 2011-06-22 2013-02-20 Людмила Николаевна Третьяк Средство для повышения адаптируемости организма к экстремальным условиям

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
WO2000038715A2 (fr) * 1998-12-23 2000-07-06 G.D. Searle & Co. Procede d'utilisation d'un antagoniste de l'integrine et radiotherapie en tant que polytherapie dans le traitement des neoplasies
ES2249253T3 (es) * 1999-03-10 2006-04-01 G.D. Searle Llc Metodo y composicion para administrar un inhibidor de la ciclooxigenasa-2.
EP1206256B8 (fr) * 1999-07-29 2005-06-29 Amgen, Inc. Therapie d'association comprenant l'administration de pentafluorobenzenesulfonamides
PT1282418E (pt) 2000-05-19 2005-10-31 Applied Research Systems Utilizacao de derivados pirazolo para o tratamento da infertilidade
WO2002039958A2 (fr) 2000-11-03 2002-05-23 Tularik Inc. Therapies combinees a base de pentafluorobenzenesulfonamides et d'agents antineoplasiques
KR100686537B1 (ko) * 2001-12-28 2007-02-27 씨제이 주식회사 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
CA2492387A1 (fr) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combinaison d'un inhibiteur allosterique carboxylique de la metalloproteinase matricielle 13 avec un inhibiteur selectif de la cyclooxygenase-2 qui n'est pas un celecoxib ou un valdecoxib
KR100484525B1 (ko) * 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
AT504159A1 (de) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc Verwendung von proteasen
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297592A1 (fr) * 1993-01-15 1994-07-21 G.D. Searle & Co. Nouveaux thiophenes 3,4-diaryliques et leurs analogues, utiles comme agents anti-inflammatoires
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
KR100229343B1 (ko) * 1993-11-30 1999-11-01 윌리암스 로저 에이 염증치료용 치환 피라졸일벤젠술폰아미드
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
JPH10511089A (ja) * 1994-12-21 1998-10-27 メルク フロスト カナダ インコーポレーテツド Cox−2阻害剤としてのジアリール−2−(5h)−フラノン
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2475257C1 (ru) * 2011-06-22 2013-02-20 Людмила Николаевна Третьяк Средство для повышения адаптируемости организма к экстремальным условиям

Also Published As

Publication number Publication date
PL194717B1 (pl) 2007-06-29
ID21979A (id) 1999-08-19
SK59999A3 (en) 2000-01-18
WO1998022101A2 (fr) 1998-05-28
PL333370A1 (en) 1999-12-06
NZ335853A (en) 2002-02-01
NO992309L (no) 1999-05-12
RO118566B1 (ro) 2003-07-30
CA2270469C (fr) 2007-04-10
EP0941080A2 (fr) 1999-09-15
CA2270469A1 (fr) 1998-05-28
AU7298298A (en) 1998-06-10
RU2268716C2 (ru) 2006-01-27
JP2001505564A (ja) 2001-04-24
CN1247470A (zh) 2000-03-15
AU730211B2 (en) 2001-03-01
IL129604A0 (en) 2000-02-29
CZ176899A3 (cs) 1999-10-13
PL191793B1 (pl) 2006-07-31
NO992309D0 (no) 1999-05-12
IL129604A (en) 2004-08-31
BR9713522A (pt) 2000-03-21
TR199901703T2 (xx) 2000-07-21
WO1998022101A3 (fr) 1998-06-25
KR20000053362A (ko) 2000-08-25

Similar Documents

Publication Publication Date Title
DE69636036T2 (de) Mittel, die einen cyclooxygenase-2 inhibitor und einen leukotrien a 4 hydrolaseinhibitor enthalten
UA67732C2 (uk) Інгібітори циклооксигенази-2 для лікування і попередження неоплазії та спосіб лікування
BG103803A (bg) Метод за приложение на инхибитори на циклооксигеназа-2 при предотвратяване на смущения в сърдечно-съдовата система
UA70294C2 (en) Use of cyclooxygenase-2 inhibitors as anti-angiogeuse of cyclooxygenase-2 inhibitors as anti-angiogenic agents nic agents
EP1526869A1 (fr) Compositions d'un inhibiteur selectif de cyclooxygenase-2 et d'un inhibiteur d'anhydrase carbonique pour traiter la neoplasie
MXPA04010888A (es) Combinacion de inhibidores de ciclooxigenasa-2 y talidomida para el tratamiento de neoplasia.
WO2004093870A1 (fr) Traitement et prevention de troubles otiques
US20050119262A1 (en) Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
CA2435835A1 (fr) Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin
US20040235925A1 (en) Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
WO2001087343A2 (fr) Polytherapie faisant appel a un inhibiteur selectif de cox-2 et a un inhibiteur de la thromboxane ainsi que des compositions contenant ceux-ci
US20020035156A1 (en) Combination therapy in the prevention of cardiovascular disorders
US20070072861A1 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
US20040121961A1 (en) Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
WO2005020926A2 (fr) Traitement ou prevention de troubles vasculaires au moyen d'inhibiteurs de cox-2 associee a des inhibiteurs de la phosphodiesterase specifique de l'amp cyclique
US20050187278A1 (en) Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
JP2007503396A (ja) 新形成の治療のためのシクロオキシゲナーゼ−2選択的阻害剤及びセロトニン−調節剤の組成物
US20040204411A1 (en) Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
WO2005049014A1 (fr) Methodes de traitement ou de prevention de troubles oculaires lies au diabete par des inhibiteurs cox-2 seuls ou en association avec des agents anti-diabete classiques
WO2005009354A2 (fr) Compositions contenant un inhibiteur selectif de la cyclooxygenase-2 et un inhibiteur des ikk, utilisees dans le traitement des troubles ou lesions d'origine ischemique du systeme nerveux central
AU2003232096A1 (en) Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxyge-nase-2 (cox 2) inhibitor(s)
US20040006100A1 (en) Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (COX 2) inhibitor(S)
MXPA99009495A (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
CZ9903642A3 (cs) Použití inhibitorů cyklooxygenasy-2 pro prevenci kardiovaskulárních onemocnění